Minoryx initating next phase in trial

“Minoryx gains FDA approval to initiate a Phase 3 clinical trial in patients with cerebral Adrenoleukodystrophy. CALYX will enroll 40 adult male X-ALD patients with progressive cALD defined by the presence of gadolinium enhancing brain lesions.”

To read the full press release: https://www.minoryx.com/media/minoryx-gains-fda-approval-to-initiate-a-phase-3-clinical-trial-in-patients-with-cerebral-adrenoleukodystrophy/